Prostate cancer (PCa) is one of the most common neoplasms in countries with increased life expectancy, the risk being directly proportional to age. The incidence of PCa in the European Union is 65 / 100,000 inhabitants / year and the mortality rate is 26 / 100,000 inhabitants / year [1].

The Romanian Cancer League estimates that 177 new cases of prostate cancer are diagnosed annually and that about 7.3% of men die annually. Prostate cancer is the second cause of cancer death after lung cancer [2]. The average age at diagnosis is 71 years. In patients deceased by other causes, localized PCa was detected in autopsy in about 7.3% of men die annually. Prostate cancer is the most common manifestation is obstructive uropathy, the most common causes of which depend on the severity of the obstruction, the onset of the onset, the single- or bilateral development of the neoplasm and the patient’s basic condition of patients and prolong survival.

Patient quality of life is severely impaired by complications (chronic renal failure, unilateral or bilateral ureterohydronephrosis, urinary retention, etc.) caused by both local and distal spread of prostate cancer. They lead to the appearance of paraneoplastic symptoms, such as unilateral or bilateral lumbar pain through obstructive uropathy, generalized asthenia, cachexia, decreased muscle strength, digestive symptoms (nausea, vomiting, in appetence). Due to the lack of specific symptomatology in locally advanced prostate cancer, urinary tract damage is insidious and ureterohydronephrosis is accidentally detected.

Urological therapeutic methods are widely used in the palliative treatment of patients with hormone refractory prostate cancer, and are needed to improve the overall condition of patients and prolong survival.

Experimental part

Materials and methods

The prospective study is conducted over a period of 4 years from 2013 to 2016 and includes a batch of 71 patients who have been hospitalized and treated in the Urology
Clinic of the Arad County Emergency Clinical Hospital. Patients enrolled in the study were diagnosed with CRPC and followed dynamically in terms of evolution following the application of palliative urological methods. It has been followed and to what extent these methods increase life expectancy and increase the quality of the survival.

Criteria for inclusion in the study: a) Patients who have signed informed consent for participation in the study; b) Patients diagnosed with CRPC - as defined by CRPC in the European Guidelines for Urology; c) The presence of two or more new bone lesions detected by radio-imaging methods and d) Patients who developed urological complications.

Histopathological examination. Tissue samples were collected from each patient and were analyzed by conventional optical microscopy or immunohistochemical methods.

The Ethics Commission of the Arad County Emergency Clinical Hospital and the Scientific Research Ethics Committee of the Vasile Goldis West University approved this study, which has complied with all ethical and ethical norms, as well as the Helsinki Declaration for studies with human subjects.

Results and discussions

Patients were monitored from the time of diagnosis of prostate cancer by tracking clinical and biological evolution, with an emphasis on selecting those patients who developed the form of cancer that became resistant to castration, with the identification of urological complications and applied urological therapeutic methods in a palliative manner. Prostate cancer becomes hormone-refractory after a 3-5 year evolution. First-line drug therapy for hormone-refractory prostate cancer is the four FDA-approved medicines for use in patients with CRPC, namely: docetaxel in combination with prednisone, cabazitaxel, abiraterone acetate and sipuleucel-T. Palliative surgery is required to relieve symptoms and ensure the quality of life of the patient and becomes a reasonable alternative when healing is not possible or when attempts to achieve healing result in adverse reactions that the patient cannot tolerate. In all these situations, urological therapeutic methods are needed to alleviate complications of advanced prostate cancer.

Histopathologically, actual, the following forms of prostate cancer are distinguished: Small cell carcinoma; Mucinous adenocarcinoma; Adenocarcinoma with signet ring cell-like features (cell in seal ring); Ductal adenocarcinoma; Basal cell carcinoma; Ainar adenocarcinoma, which presents the following histopathological changes - mucinous fibroplasia, carcinoma foamy gland, Neuroendocrine differentiation Paneth-like cells; Prostate adenocarcinoma treated by radiotherapy; Pseudo-hyperplastic prostatic adenocarcinoma; Intraductal prostatic carcinoma [7].

Histopathological results help to determine the prognosis and grouping of patients by the Gleason score and disease status group provided by the TNM classification.

The Gleason score is based exclusively on the microscopic aspects of tumor glands at small targets. Initially, only Gleason grades were defined, which were defined from 1 to 5 (grade 1 being the most differentiated model, and grade 5 poorly differentiated or undifferentiated carcinoma); then the Gleason score was introduced, which aims at identifying two architectural models - the primary model, predominantly the model of secondary importance [8].

Gleason grades are: Grade 1 - cancerous tissue is very similar to normal prostatic tissue; grade 2 - the presence of well-defined glands, but of larger size; grade 3 - darker cells, go beyond the glandular structure and invade neighboring tissue; grade 4 - very few glands, invasion of neighboring tissue; grade 5 - absent glands.

Interpretation of the Gleason score: Gleason 2-4 - well differentiated tumor; Gleason 5-7 - moderately differentiated tumor; Gleason 8-10 - undifferentiated tumor [9].

It is considered that the prognosis of the disease is influenced by both primary and secondary architectural aspects, they are summed up resulting in a combined Gleason grade - Gleason score [9], so the Gleason score is higher, the more serious the neoplastic disease is.

Looking at the study as a whole, there are 6 patients, 2 with Gleason score 5 and 4 with Gleason score of 6 who were included in risk group 1, indicating a less aggressive form of neoplasia (see histopathological examination in figs. 1, 2). Current discussions about prostate cancer with Gleason score d"6 are related to the need to initiate antandrogenic therapy or to apply active surveillance to the patient. Some scientists consider that these grades should not be treated. However, we should note that in our study there are patients with Gleason score ≤ 6 and 8.45% of the total of 71 cases that have turned into hormone-refractory prostate cancer. This may be due either to the possibility of negative progression of prostate cancers with Gleason score ≤ 6, or omission during prostate biopsy or surgical intervention of a prostate cancer with a higher Gleason score.

Even if we have a total of 37 patients with a Gleason score of 7, their prognosis is different depending on the primary and secondary architectural aspects of the tumor. Thus, we have 11 patients with a Gleason score of 7 (3 + 4) falling within prognostic group 3, with a 15.49% score. Unfortunately, in this study, the majority of patients, 26 patients - 36.61%, were included in prognostic group 4 of patients with Gleason score of 7 (4 + 3). Within the prognostic group 5 a number of 28 patients were enrolled, representing 39.44% and a number of 22 patients with Gleason score 8 and 6 patients with Gleason 9 score, almost maximal were identified. Looking at the whole group of patients with CRPC, we have a total of 76.04% including the patients with a Gleason score of 7 (4 + 3), 8, 9, which in terms of prognosis is in the one with aggressive evolution. This percentage is considered high and should
be taken into account particularly in terms of palliative methods that had to be recommended along the course of the disease.

Conclusions

The main conclusions of this study are the following: the provenance environment is not a risk factor for the development of CRPC; patients with CRPC have a number of complications, among which the most serious is unilateral or bilateral ureterohydronephrosis, which evolves to IRC; most patients diagnosed with CRPC were classified as unfavorable prognostic groups; patients in the adverse prognostic groups had more frequent secondary anemia and bone metastases; anemia that occurs in patients with CRPC causes an increase in the prevalence of comorbid associations; the most recommended oncological treatment was total androgenic blockade.

References


Manuscript received: 15.02.2017